EphA2 is a predictive biomarker of resistance and a potential therapeutic target for improving antiepidermal growth factor receptor therapy in colorectal cancer

G. Martini, C. Cardone, P.P. Vitiello, V. Belli, S. Napolitano, T. Troiani, D. Ciardiello, C.M. Della Corte, F. Morgillo, N. Matrone, V. Sforza, G. Papaccio, V. Desiderio, M.C. Paul, V. Moreno-Viedma, N. Normanno, A.M. Rachiglio, V. Tirino, E. Maiello, T.P. LatianoD. Rizzi, G. Signoriello, M. Sibilia, F. Ciardiello, E. Martinelli

Research output: Contribution to journalArticlepeer-review

Cite this